Key result
Bevacizumab increases cardiomyocyte apoptosis up to ~30% in vitro via mitochondrial and ER stress.
Why the study?
The molecular mechanisms underlying the cardiotoxicity associated with bevacizumab, a first-line immunotherapeutic agent used to treat lung cancer, are not fully understood.
Does bevacizumab induce cardiotoxicity through mitochondrial dysfunction, ER stress, and ERK inactivation in cardiomyocytes in vitro?
Does bevacizumab induce cardiotoxicity through mitochondrial dysfunction, ER stress, and ERK inactivation in cardiomyocytes in vitro?
Bevacizumab induces cardiotoxicity in vitro via mitochondrial dysfunction, ER stress, and ERK pathway inactivation, highlighting potential therapeutic targets to mitigate myocardial injury during immunotherapy.
Answers are grounded in this paper and cite their sources.
May signal cardiotoxicity risk with bevacizumab; leaves open in vivo validation and pathway-targeted mitigation in patients.
The molecular mechanisms underlying the cardiotoxicity associated with bevacizumab, a first‐line immunotherapeutic agent used to treat lung cancer, are not fully understood. Here, we examined intracellular signal transduction in cardiomyocytes after exposure to different doses of bevacizumab in vitro . Our results demonstrated that bevacizumab significantly and dose‐dependently reduces cardiomyocyte viability and increases cell apoptosis. Bevacizumab treatment also led to mitochondrial dysfunction in cardiomyocytes, as evidenced by the decreased ATP production, increased ROS production, attenuated antioxidative enzyme levels, and reduced respiratory complex function. In addition, bevacizumab induced intracellular calcium overload, ER stress, and caspase‐12 activation. Finally, bevacizumab treatment inhibited the ERK signaling pathway, which, in turn, significantly reduced cardiomyocyte viability and contributed to mitochondrial dysfunction. Together, our results demonstrate that bevacizumab‐mediated cardiotoxicity is associated with mitochondrial dysfunction, ER stress, and ERK pathway inactivation. These findings may provide potential treatment targets to attenuate myocardial injury during lung cancer immunotherapy.
No takes yet. Share an insight, caveat, or question.
Li et al. (2021) studied Bevacizumab-induced cardiotoxicity. Bevacizumab vs. Untreated control cardiomyocytes was evaluated on Cardiomyocyte viability and apoptosis rate (p=<0.05). Bevacizumab dose-dependently reduced cardiomyocyte viability and increased apoptosis up to ~30% in vitro via mitochondrial dysfunction, ER stress, and ERK pathway inactivation.
Synapse has enriched 10 related papers. Consider them for comparative context: